Raporty Spółek ESPI/EBI

Publication of the Annual Audited Consolidated Financial Statements of "Sopharma" AD for 2025 SOPHARMA AD (BG11SOSOBT18)

29-04-2026 09:32:06 | ESPI | 128/2026
oUNI-EN: Publication of the Annual Audited Consolidated Financial Statements of "Sopharma" AD for 2025

 PAP
Data: 2026-04-29
Firma: SOPHARMA AD
oSpis tresci:
1. REPORT
2. INFORMATION ABOUT THE ENTITY
3. SIGNATURE OF PERSONS REPRESENTING THE COMPANY

oSpis zalacznikow:
Znaleziono 1 załącznik
  • 097900BGGW0000048796-20251231-EN-CON.zip
    		•  Arkusz: REPORT

    Nazwa arkusza: REPORT


    POLISH FINANCIAL SUPERVISION AUTHORITY
    UNI - EN REPORT No 128 / 2026
    Date of issue: 2026-04-29
    Short name of the issuer
    SOPHARMA AD
    Subject
    Publication of the Annual Audited Consolidated Financial Statements of "Sopharma" AD for 2025
    Official market - legal basis
    Art. 56. 1. 2 of Act on Public Offering
    Unofficial market - legal basis
    Contents of the report:
    Sofia, Bulgaria, 29 April 2026 - According to the requirements of art. 100n of LPOS, "Sopharma" AD _SFA: "BSE-Sofia" AD, SPH: Warsaw Stock Exchange_ presents the Annual Audited Consolidated Financial Statements, which contains:

    - XHTML format of the report in accordance with the requirements of Commission Delegated Regulation _EU_ 2018/815 of 17 December 2018 supplementing Directive 2004/109/EC of the European Parliament and of the Council with regulatory technical standards on the definition of a common electronic format for reports. It contains:
    - Annual consolidated financial statements
    - Notes to the annual consolidated financial statements
    - Annual consolidated management report
    - Corporate Governance Declaration
    - Declaration by the responsible persons
    - Audit report

    - Annual reports according to a template determined by the Deputy Chairman of the Financial Supervision Commision;
    - Electronic reference to the published inside information under Article 7 of Regulation _EU_ ą596 / 2014 of the European Parliament and of the Council of 16 April 2014 on market abuse _Market Abuse Regulation_ and repealing Directive 2003/6/EC of the European Parliament and of the Council and Commission Directives 2003/124/EC, 2003/125/EC and 2004/72/EC _OJ L 173/1 of 12 June 2014_ _Regulation _EU_ ą 596/2014_ on the circumstances during the past year:
    http://www.x3news.com/?page=News_uniqid=6242d3eba9dc7 https://www.sopharmagroup.com/bg/investitori/novini-za-investitori

    Annexes
    File Description
    097900BGGW0000048796-20251231-EN-CON.zip Publication of the Annual Audited Consolidated Financial Statements of "Sopharma" AD for 2025

    Nazwa arkusza: INFORMATION ABOUT THE ENTITY


    SOPHARMA AD
    _fullname of the issuer_
    SOPHARMA AD Farmaceutyczny _far_
    _short name of the issuer_ _sector according to clasification
    of the WSE in Warsow_
    1220 Sofia
    _post code_ _city_
    IlienskoShosse 16
    _street_ _number_
    +359 2 813 42 00 +359 2 936 02 86
    _phone number_ _fax_
    _e-mail_ _web site_
    nd
    _NIP_ _REGON_

    Nazwa arkusza: SIGNATURE OF PERSONS REPRESENTING THE COMPANY


    SIGNATURE OF PERSONS REPRESENTING THE COMPANY
    Date Name Position / Function Signature
    2026-04-29 Ognian Ivanov Donev Executive Director


    Identyfikator raportu jjvuszwyf1
    Nazwa raportu UNI-EN
    Symbol raportu UNI-EN
    Nazwa emitenta SOPHARMA AD
    Symbol Emitenta SOPHARMA AD
    Tytul Publication of the Annual Audited Consolidated Financial Statements of "Sopharma" AD for 2025
    Sektor Farmaceutyczny (far)
    Kod 1220
    Miasto Sofia
    Ulica IlienskoShosse
    Nr 16
    Tel. +359 2 813 42 00
    Fax +359 2 936 02 86
    e-mail
    NIP nd
    REGON
    Data sporzadzenia
    Rok biezacy 2026
    Numer 128
    adres www
    Serwis Ekonomiczny Polskiej Agencji Prasowej SA 2026 Copyright PAP SA - Wszelkie prawa zastrzezone.